Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Palisade Bio Inc. (PALI:NASDAQ), powered by AI.
Palisade Bio Inc. is currently trading at $1.78. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Palisade Bio Inc. on Alpha Lenz.
Palisade Bio Inc.'s P/E ratio is -5.9.
“Palisade Bio Inc. trades at a P/E of -5.9 (undervalued) with modest ROE of -24.5%.”
Ask for details →Palisade Bio Inc. is a clinical-stage biopharmaceutical company dedicated to advancing drug therapies aimed at improving the safety and efficacy of treatments for acute and chronic gastrointestinal complications. Known for its targeted focus on enhancing surgical outcomes, Palisade Bio's primary asset is its lead investigational drug candidate, designed to mitigate intestinal permeability and reduce related post-operative complications. The company's research initiatives are significant in medical areas such as gastrointestinal diseases, underscoring its commitment to innovations that potentially benefit patient recovery and healthcare systems. By developing solutions that aim to improve patient quality of life during surgical recoveries, Palisade Bio plays a vital role in the biotechnology sector, particularly in gastrointestinal health. Headquartered in Carlsbad, California, the company's efforts contribute to the broader field of biopharmaceutical development, positioning it as a key player in addressing unmet medical needs.
“Palisade Bio Inc. trades at a P/E of -5.9 (undervalued) with modest ROE of -24.5%.”
Ask for details →Palisade Bio Inc. (ticker: PALI) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 8 employees. Market cap is $99M.
The current price is $1.78 with a P/E ratio of -5.91x and P/B of 0.77x.
ROE is -24.52%.